Drugs / TEZACITABINE ANHYDROUS
TEZACITABINE ANHYDROUS
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00061620 | Sep 2001 → Feb 2004 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00054873 | Nov 2003 → Dec 2004 | adenocarcinoma, gastric neoplasm, neoplasm of esophagus | Chiron Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00051688 | Jun 2003 → Aug 2004 | colorectal cancer | Chiron Corporation | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZACITABINE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Known as | FMD-C | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Known as | KW-2331 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Known as | MDL-101731 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Known as | Tezacitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Known as | Tezacitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00061620 ↗ |
| Known as | Tezacitabine monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105467 ↗ |
| Modality | Other / unclassified | “Tezacitabine is a nucleoside analogue” NCT00061620 ↗ |
| Route | Intravenous | “continuous infusion by vein” NCT00061620 ↗ |